Back to search
Toxoplasma Gondii Infection
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Toxoplasma Gondii Infection trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Toxoplasma Gondii Infection trials you may qualify forRACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capa…
Chronic Toxoplasma gondii (T. gondii) infection is a widespread condition that can negatively affect brain function and is considered a risk factor for various…
Toxoplasmosis in HIV-positive individuals is well-studied and has a codified management protocol, which is not the case for other immunodeficiencies, except for…
This is part of a feasibility study to compare the predicate standard FDA cleared test for serum to a point of care test Toxoplasma ICT IgG-IgM BK produced by L…
Toxoplasmosis is a common infection whose clinical severity can sometimes justify admission to intensive care, especially in immunocompromised patients. This s…
Toxoplasma gondii infects over one third of the global human population. Cerebral toxoplasmosis is the most common opportunistic infection in HIV patients resul…
The Toxoplasma gondii parasite causes toxoplasmosis. It is characterized by persistent cysts mostly localised in the brain and ocular areas. In the case of immu…
Toxoplasmosis in immunocompromised patients is a serious, life-threatening condition that requires rapid, appropriate treatment. Diagnosis is based on PCR, nota…
This study looks at patients who were treated for cerebral toxoplasmosis at CHSD between 2004 and 2024. It focuses on analyzing their cerebrospinal fluid (CSF)…